Evidence map›Paper›PMID 41245812›Full record

ArticleJAC-antimicrobial resistance2025

Circulation of polyclonal OXA-244-producing

Janko Sattler, Yonatan Oster, Helena M B Seth Smith, Yukino Gütlin, Ayelet Michael-Gayego, Dan Reshef, Violeta Temper, Karsten Borgwardt, Adrian Egli, Jacob Strahilevitz and 1 more

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Janko SattlerDepartment of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.
Yonatan OsterDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0002-1050-1648
Helena M B Seth SmithInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Yukino GütlinInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Ayelet Michael-GayegoDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Dan ReshefDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Violeta TemperDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Karsten BorgwardtDepartment of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.ORCID https://orcid.org/0000-0001-7221-2393
Adrian EgliInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-3564-8603
Jacob StrahilevitzDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Jacob Moran-GiladDepartment of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.ORCID https://orcid.org/0000-0001-9134-050X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: OXA-244-producing Patients and methods: In 2024, 171 patients were identified with OXA-48-like-producing Results: Amongst the 53 sequenced OXA-48-like-producing Conclusions: This study demonstrates the predominance of OXA-244-producing

Identifiers

PMID41245812
PMCPMC12611639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.